Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Lifecare AS ( (DE:LFC0) ) is now available.
Lifecare ASA has shared promising results from its ongoing LFC-SEN-002 longevity study, which evaluates the long-term performance and biocompatibility of its implantable continuous glucose monitor. The study, conducted with the Norwegian University of Life Sciences, confirms the biocompatibility and safety of the implants in dogs, with no adverse reactions observed. The findings have led to technical improvements in the next generation of implants, including better signal-to-noise ratio and enhanced material stability. These insights are crucial for Lifecare’s preparation for a veterinary market launch and human clinical trials in 2026, supporting their regulatory and product development efforts.
More about Lifecare AS
Lifecare ASA is a MedTech company specializing in the development of next-generation implantable Continuous Glucose Monitoring (CGM) technology. The company focuses on bringing advanced CGM systems to market, leveraging osmotic pressure as a sensing principle. Their technology is designed for monitoring various body analytes in both humans and pets.
Average Trading Volume: 397,128
Current Market Cap: NOK99.49M
For detailed information about LFC0 stock, go to TipRanks’ Stock Analysis page.